Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients

Zhe Zhang; Shipo Wu; Yawei Liu; Kailiang Li; Pengfei Fan; Xiaohong Song; Yudong Wang; Zhenghao Zhao; Xianwei Zhang; Jin Shang; Jinlong Zhang; Jinghan Xu; Yao Li; Yaohui Li; Jipeng Zhang; Kefan Fu; Busen Wang; Meng Hao; Guanying Zhang; Pengwei Long; Ziyu Qiu; Tao Zhu; Shuling Liu; Yue Zhang; Fangze Shao; Peng Lv; Yilong Yang; Xiaofan Zhao; Yufa Sun; Lihua Hou; Wei Chen

doi:10.3389/fimmu.2023.1239179

Frontiers in Immunology (Oct 2023)

Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients

Zhe Zhang,
Shipo Wu,
Yawei Liu,
Kailiang Li,
Pengfei Fan,
Xiaohong Song,
Yudong Wang,
Zhenghao Zhao,
Xianwei Zhang,
Jin Shang,
Jinlong Zhang,
Jinghan Xu,
Yao Li,
Yaohui Li,
Jipeng Zhang,
Kefan Fu,
Busen Wang,
Meng Hao,
Guanying Zhang,
Pengwei Long,
Ziyu Qiu,
Tao Zhu,
Shuling Liu,
Yue Zhang,
Fangze Shao,
Peng Lv,
Yilong Yang,
Xiaofan Zhao,
Yufa Sun,
Lihua Hou,
Wei Chen

Affiliations

Zhe Zhang: Beijing Institute of Biotechnology, Beijing, China
Shipo Wu: Beijing Institute of Biotechnology, Beijing, China
Yawei Liu: Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China
Kailiang Li: Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China
Pengfei Fan: Beijing Institute of Biotechnology, Beijing, China
Xiaohong Song: Beijing Institute of Biotechnology, Beijing, China
Yudong Wang: Beijing Institute of Biotechnology, Beijing, China
Zhenghao Zhao: Beijing Institute of Biotechnology, Beijing, China
Xianwei Zhang: Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China
Jin Shang: Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China
Jinlong Zhang: Beijing Institute of Biotechnology, Beijing, China
Jinghan Xu: Beijing Institute of Biotechnology, Beijing, China
Yao Li: Beijing Institute of Biotechnology, Beijing, China
Yaohui Li: Beijing Institute of Biotechnology, Beijing, China
Jipeng Zhang: Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China
Kefan Fu: Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China
Busen Wang: Beijing Institute of Biotechnology, Beijing, China
Meng Hao: Beijing Institute of Biotechnology, Beijing, China
Guanying Zhang: Beijing Institute of Biotechnology, Beijing, China
Pengwei Long: Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China
Ziyu Qiu: Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China
Tao Zhu: CanSino Biologics Inc., Tianjin, China
Shuling Liu: Beijing Institute of Biotechnology, Beijing, China
Yue Zhang: Beijing Institute of Biotechnology, Beijing, China
Fangze Shao: Beijing Institute of Biotechnology, Beijing, China
Peng Lv: Beijing Institute of Biotechnology, Beijing, China
Yilong Yang: Beijing Institute of Biotechnology, Beijing, China
Xiaofan Zhao: Beijing Institute of Biotechnology, Beijing, China
Yufa Sun: Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China
Lihua Hou: Beijing Institute of Biotechnology, Beijing, China
Wei Chen: Beijing Institute of Biotechnology, Beijing, China

DOI: https://doi.org/10.3389/fimmu.2023.1239179
Journal volume & issue: Vol. 14

Abstract

Read online

IntroductionThe SARS-CoV-2 Omicron variant has become the dominant SARS-CoV-2 variant and exhibits immune escape to current COVID-19 vaccines, the further boosting strategies are required.MethodsWe have conducted a non-randomized, open-label and parallel-controlled phase 4 trial to evaluate the magnitude and longevity of immune responses to booster vaccination with intramuscular adenovirus vectored vaccine (Ad5-nCoV), aerosolized Ad5-nCoV, a recombinant protein subunit vaccine (ZF2001) or homologous inactivated vaccine (CoronaVac) in those who received two doses of inactivated COVID-19 vaccines. ResultsThe aerosolized Ad5-nCoV induced the most robust and long-lasting neutralizing activity against Omicron variant and IFNg T-cell response among all the boosters, with a distinct mucosal immune response. SARS-CoV-2-specific mucosal IgA response was substantially generated in subjects boosted with the aerosolized Ad5-nCoV at day 14 post-vaccination. At month 6, participants boosted with the aerosolized Ad5-nCoV had remarkably higher median titer and seroconversion of the Omicron BA.4/5-specific neutralizing antibody than those who received other boosters. DiscussionOur findings suggest that aerosolized Ad5-nCoV may provide an efficient alternative in response to the spread of the Omicron BA.4/5 variant.Clinical trial registrationhttps://www.chictr.org.cn/showproj.html?proj=152729, identifier ChiCTR2200057278.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords